Verified employee & interview reviews

Lupin Reviews

Mumbai, Maharashtra

4.3/ 5

3 reviews

Lupin Limited is an innovation-led, transnational pharmaceutical company headquartered in Mumbai, Maharashtra, India. Founded in 1968 by Dr. Desh Bandhu Gupta, a chemistry professor who initially borrowed INR 5,000 from his wife to fund the venture, Lupin has grown from a small generic vitamin manufacturer into a global pharmaceutical powerhouse. Today, it ranks as one of the largest generic pharmaceutical companies globally by market capitalization and stands as the third-largest pharmaceutical company in India by revenue. The company operates across the entire pharmaceutical value chain, encompassing the development, manufacturing, and commercialization of branded and generic formulations, active pharmaceutical ingredients (APIs), advanced drug delivery systems, biotechnology products, and biosimilars. Lupin’s extensive product portfolio addresses key therapeutic areas including cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infectives, oncology, and women’s health. Notably, Lupin first gained global recognition as one of the world's largest manufacturers of anti-tuberculosis (TB) medications and continues to hold a global leadership position in the anti-TB and cephalosporins market segments. Lupin maintains a highly diversified global footprint, commercializing its products in over 100 markets across North America, Europe, South Africa, Latin America, the Asia-Pacific region, and the Middle East. The United States serves as a critical revenue driver for the organization, where its subsidiary, Lupin Pharmaceuticals Inc., operates out of Baltimore, Maryland. In the U.S. market, Lupin stands as the third-largest generic pharmaceutical company by prescription-led market share and is a market leader across dozens of generic products. The company also maintains a significant presence in emerging markets, supported by a network of 12 manufacturing plants and dedicated research centers located across India and various international territories. Financially, Lupin is a publicly traded entity listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker symbol LUPIN. For the trailing twelve months leading into early 2026, the company reported consolidated revenues of approximately $3.11 billion and an operating income of roughly $550 million. The organization is steered by its core leadership team, which includes Chief Executive Officer Vinita D. Gupta and Managing Director Nilesh Gupta, both of whom have guided the firm's transition into complex generics, biosimilars, and digital healthcare services. In addition to commercial metrics, Lupin places a strong emphasis on sustainability and corporate social responsibility. The company’s dedicated CSR arm, the Lupin Human Welfare & Research Foundation, has impacted millions of lives across thousands of Indian villages since its establishment in 1988, focusing on sustainable rural development and healthcare access.